On May 17, 2025, Fractyl Health, Inc. announced new preclinical data for its Rejuva gene therapy platform at a major conference, showcasing its potential for effective GLP-1 secretion and readiness for human trials. The first Clinical Trial Application for RJVA-001 is expected by June 2025.